A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain
← catalyst calendarNCT06746116 · readout in 834 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Apices Soluciones S.L..
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
45actual
Sites
24
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-30 | actual | When the study began enrolling |
| Primary completion | 2028-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced or Recurrent Endometrial Cancer
Interventions
- Drug: Durvalumab + Chemotherapy phase — also filed as Chemotherapy phase
- Drug: Durvalumab + Olaparib phase — also filed as Maintenance phase
Primary outcome
what the primary-completion date above is the date OFNumber of patients with Adverse Events
measured Time from enrollment up to at least 90 days after last dose of study treatment
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed